EMBC vs. NARI, IRTC, NVCR, ICUI, IART, UFPT, LMAT, ATEC, MDXG, and ATRC
Should you be buying Embecta stock or one of its competitors? The main competitors of Embecta include Inari Medical (NARI), iRhythm Technologies (IRTC), NovoCure (NVCR), ICU Medical (ICUI), Integra LifeSciences (IART), UFP Technologies (UFPT), LeMaitre Vascular (LMAT), Alphatec (ATEC), MiMedx Group (MDXG), and AtriCure (ATRC). These companies are all part of the "surgical & medical instruments" industry.
Inari Medical (NASDAQ:NARI) and Embecta (NASDAQ:EMBC) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, community ranking, dividends, media sentiment, valuation and earnings.
Inari Medical has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, Embecta has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.
Embecta has a net margin of 6.20% compared to Embecta's net margin of -4.54%. Embecta's return on equity of -1.65% beat Inari Medical's return on equity.
Inari Medical currently has a consensus target price of $65.71, indicating a potential upside of 29.64%. Embecta has a consensus target price of $13.00, indicating a potential upside of 4.59%. Given Embecta's stronger consensus rating and higher probable upside, equities analysts clearly believe Inari Medical is more favorable than Embecta.
Embecta has higher revenue and earnings than Inari Medical. Inari Medical is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.
91.0% of Inari Medical shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 10.6% of Inari Medical shares are held by insiders. Comparatively, 0.3% of Embecta shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Inari Medical had 18 more articles in the media than Embecta. MarketBeat recorded 21 mentions for Inari Medical and 3 mentions for Embecta. Inari Medical's average media sentiment score of 1.84 beat Embecta's score of 0.26 indicating that Embecta is being referred to more favorably in the news media.
Inari Medical received 58 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 68.24% of users gave Inari Medical an outperform vote while only 0.00% of users gave Embecta an outperform vote.
Summary
Inari Medical beats Embecta on 10 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding EMBC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
